Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
- Symbol
- RFL
- Exchange
- NYSE
- Sector
- Real Estate
- Industry
- Real Estate Services
- Market cap
- $102.46M
- 52 week range
- 1.12 - 3.96
Valuation
- Share price
- $2.02 (close of 2026-09-23)
- P/E (TTM)
- -2.90x
- Price to book
- 1.27x
- Price to free cash flow
- -3.20x
- Enterprise value
- $72.57M
- Book value per share
- $1.58
Price performance
| Period | Change |
|---|
| 1 day | +1.00% |
| 5 days | -5.61% |
| 1 month | -6.48% |
| 3 months | -24.34% |
| 6 months | +60.32% |
| Year to date | +71.19% |
| 1 year | +38.36% |
| 3 years | +2.54% |
| 5 years | -94.55% |
| All time | -58.18% |
Profitability and growth
- Return on equity
- -31.03%
- Return on invested capital
- -58.34%
- Return on assets
- -26.75%
- Return on capital employed
- -28.45%
- Net margin
- -101733.33%
- EBITDA margin
- -96236.67%
- Revenue growth
- -95.29%
- Net income growth
- 11.30%
- Free cash flow growth
- -138.24%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -31.23%
- Current ratio
- 3.16x
- Net debt to EBITDA
- 0.96x
Latest reported year
- Period end
- 2025-07-31
- Fiscal year
- 2025
- Revenue
- $30.00K
- EBITDA
- $-28.87M
- Net income
- $-30.52M
- Earnings per share
- $-1.04
- Research and development
- $12.82M
- Interest expense
- $658.00K
- Shares outstanding
- 29.42M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-07-31 | $30.00K | - | $-30.52M | $-1.04 |
| 2024-07-31 | $637.00K | $483.00K | $-34.41M | $-1.45 |
| 2023-07-31 | $279.00K | $201.00K | $-1.88M | $-0.08 |
| 2022-07-31 | $410.00K | $-3.09M | $-124.66M | $-6.22 |
| 2021-07-31 | $802.00K | $-2.37M | $-23.06M | $-1.47 |
| 2020-07-31 | $4.91M | $3.04M | $-10.75M | $-0.65 |
| 2019-07-31 | $4.93M | $3.15M | $-4.69M | $-0.35 |
| 2018-07-31 | $4.37M | $2.67M | $-11.65M | $-0.92 |
| 2017-07-31 | $5.62M | $3.95M | $138.00K | $0.01 |
| 2016-07-31 | $5.59M | $3.95M | $710.00K | $0.06 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-07-31 | - | -101733.33% | -31.03% | -58.34% |
| 2024-07-31 | 75.82% | -5401.88% | -39.89% | -116.26% |
| 2023-07-31 | 72.04% | -672.40% | -1.94% | -19.68% |
| 2022-07-31 | -753.41% | -30404.39% | -128.24% | -70.59% |
| 2021-07-31 | -295.14% | -2875.44% | -16.87% | -21.89% |
| 2020-07-31 | 62.00% | -219.00% | -8.24% | -6.81% |
| 2019-07-31 | 63.92% | -95.17% | -3.76% | -5.92% |
| 2018-07-31 | 61.15% | -266.51% | -10.03% | -3.83% |
| 2017-07-31 | 70.29% | 2.46% | 0.22% | 0.31% |
| 2016-07-31 | 70.60% | 12.70% | 1.45% | 1.60% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-07-31 | $52.77M |
| 2024-07-31 | $2.67M |
| 2023-07-31 | $21.50M |
| 2022-07-31 | $26.54M |
| 2021-07-31 | $7.85M |
| 2020-07-31 | $6.21M |
| 2019-07-31 | $12.02M |
| 2018-07-31 | $15.80M |
| 2017-07-31 | $11.76M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-07-31 | $-18.93M | $2.12M |
| 2024-07-31 | $-7.95M | $2.30M |
| 2023-07-31 | $-10.89M | $2.19M |
| 2022-07-31 | $-26.08M | $-917.00K |
| 2021-07-31 | $-15.81M | $6.63M |
| 2020-07-31 | $-5.20M | $684.00K |
| 2019-07-31 | $-3.53M | - |
| 2018-07-31 | $-2.52M | $51.00K |
| 2017-07-31 | $-3.44M | - |
| 2016-07-31 | $-1.48M | - |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-06-11 | Apr/2026 | - |
| 2026-03-16 | - | - |
| 2025-12-11 | - | - |
| 2025-10-29 | - | - |
| 2025-06-11 | - | - |
| 2025-03-13 | - | - |
| 2024-12-11 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- rafaelholdings.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
CoStar Group, Inc. (CSGP) · VICI Properties Inc. (VICI) · Welltower Inc. (WELL) · Ventas, Inc. (VTR) · Healthpeak Properties, Inc. (DOC) · Host Hotels & Resorts, Inc. (HST) · Prologis, Inc. (PLD) · Public Storage (PSA)
All Real Estate companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades